These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 28818671)

  • 1. Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies.
    Santoni M; Guerra F; Conti A; Lucarelli A; Rinaldi S; Belvederesi L; Capucci A; Berardi R
    Cancer Treat Rev; 2017 Sep; 59():123-131. PubMed ID: 28818671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does the addition of drugs targeting the vascular endothelial growth factor pathway to first-line chemotherapy increase complete response? A meta-analysis of randomized clinical trials.
    Li Y; Liang XY; Yue YQ; Sheng L; Liu JK; Wang ZY; Chen G
    Tumour Biol; 2016 May; 37(5):6297-306. PubMed ID: 26619847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials.
    Santoni M; Conti A; Andrikou K; Bittoni A; Lanese A; Pistelli M; Pantano F; Vincenzi B; Armento G; Massari F; Tonini G; Cascinu S; Santini D
    Crit Rev Oncol Hematol; 2015 Nov; 96(2):206-19. PubMed ID: 26070625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of Hyponatraemia in Cancer Patients Treated with Targeted Therapies: A Systematic Review and Meta-Analysis of Clinical Trials.
    Berardi R; Santoni M; Rinaldi S; Nunzi E; Smerilli A; Caramanti M; Morgese F; Torniai M; Savini A; Fiordoliva I; Onofri A; Pistelli M; Taccaliti A; Cascinu S
    PLoS One; 2016; 11(5):e0152079. PubMed ID: 27167519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials.
    Hang XF; Xu WS; Wang JX; Wang L; Xin HG; Zhang RQ; Ni W
    Eur J Clin Pharmacol; 2011 Jun; 67(6):613-23. PubMed ID: 21243343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients.
    Liu B; Ding F; Liu Y; Xiong G; Lin T; He D; Zhang Y; Zhang D; Wei G
    Oncotarget; 2016 Oct; 7(41):67661-67673. PubMed ID: 27602778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of fatigue in cancer patients receiving anti-EGFR monoclonal antibodies: results from a systematic review and meta-analysis of randomized controlled trial.
    Zhu J; Zhao W; Liang D; Li G; Qiu K; Wu J; Li J
    Int J Clin Oncol; 2018 Apr; 23(2):389-399. PubMed ID: 29181651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemorrhagic events in cancer patients treated with aflibercept: a meta-analysis.
    Peng L; Bu Z; Zhou Y; Ye X; Liu J; Zhao Q
    Tumour Biol; 2014 Sep; 35(9):9419-27. PubMed ID: 24957040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and risk of severe infections associated with aflibercept in cancer patients: a systematic review and meta-analysis.
    Zhang X; Ran Y; Shao Y; Wang K; Zhu Y
    Br J Clin Pharmacol; 2016 Jan; 81(1):33-40. PubMed ID: 26331893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies.
    Santoni M; Conti A; Massari F; Di Nunno V; Faloppi L; Galizia E; Morbiducci J; Piva F; Buti S; Iacovelli R; Ferretti B; Cimadamore A; Scarpelli M; Lopez-Beltran A; Cheng L; Battelli N; Montironi R
    Expert Rev Cardiovasc Ther; 2019 Dec; 17(12):917-927. PubMed ID: 31829045
    [No Abstract]   [Full Text] [Related]  

  • 11. Incidence and risk of proteinuria with aflibercept in cancer patients: a meta-analysis.
    Peng L; Zhao Q; Ye X; Zhou Y; Hu D; Zheng S
    PLoS One; 2014; 9(11):e111839. PubMed ID: 25365378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and risk of hypertension associated with ramucirumab in cancer patients: A systematic review and meta-analysis.
    Qi WX; Fu S; Zhang Q; Guo XM
    J Cancer Res Ther; 2016; 12(2):775-81. PubMed ID: 27461650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Schutz FA; Je Y; Richards CJ; Choueiri TK
    J Clin Oncol; 2012 Mar; 30(8):871-7. PubMed ID: 22312105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab increases the risk of infections in cancer patients: A systematic review and pooled analysis of 41 randomized controlled trials.
    Qi WX; Fu S; Zhang Q; Guo XM
    Crit Rev Oncol Hematol; 2015 Jun; 94(3):323-36. PubMed ID: 25749417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and relative risk of hemorrhagic events associated with ramucirumab in cancer patients: a systematic review and meta-analysis.
    Tian R; Yan H; Zhang F; Sun P; Zheng X; Zhu Y; Wang Q; He J
    Oncotarget; 2016 Oct; 7(40):66182-66191. PubMed ID: 27507055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of hypertension in cancer patients treated with aflibercept: a systematic review and meta-analysis.
    Qi WX; Shen Z; Tang LN; Yao Y
    Clin Drug Investig; 2014 Apr; 34(4):231-40. PubMed ID: 24493142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials.
    Hou W; Ding M; Li X; Zhou X; Zhu Q; Varela-Ramirez A; Yi C
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2407-2420. PubMed ID: 33725154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematologic toxicity assessment in solid tumor patients treated with cetuximab: a pooled analysis of 18 randomized controlled trials.
    Cui R; Chu L; Liu ZQ; Xiao YY; Zhu XL; Chen YJ; Xu Q
    Int J Cancer; 2015 Feb; 136(4):936-44. PubMed ID: 24975040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of cardiovascular adverse events in patients with solid tumors treated with ramucirumab: A meta analysis and summary of other VEGF targeted agents.
    Abdel-Rahman O; ElHalawani H
    Crit Rev Oncol Hematol; 2016 Jun; 102():89-100. PubMed ID: 27129437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.
    Ranpura V; Hapani S; Chuang J; Wu S
    Acta Oncol; 2010 Apr; 49(3):287-97. PubMed ID: 20156114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.